Status:

COMPLETED

The Feasibility and Safety of No-scar Transanal Total Mesorectal Excision for Rectal Cancer

Lead Sponsor:

Sun Yat-sen University

Conditions:

Rectal Cancer

Surgery

Eligibility:

All Genders

18-70 years

Phase:

PHASE1

PHASE2

Brief Summary

During the past three years, a revolutionized radical surgical approach for rectal cancer ("down to up TME " approach or "transanal TME (TaTME)"approach, which is opposite to the conventional approach...

Detailed Description

Transanal total mesorectal excision (TaTME) is a novel development in the field of colorectal surgery which combines the mini-invasive concept of natural orifice transluminal endoscopic surgery(NOTES)...

Eligibility Criteria

Inclusion

  • Biopsy-proven adenocarcinoma of the rectum
  • No previous abdominal surgery, no distant metastasis or synchronous colon cancer
  • BMI≤ 35kg/m2
  • Clinical staging (T1 or T2 or T3) with N1-2M0
  • Patients of rectal adenocarcinoma with T3N0 or N (+) received preoperative concurrent chemoradiotherapy (CCRT) as neoadjuvant therapy
  • Rectal cancer located 4-12 cm from the anal verge
  • The diameter of primary tumor should \<6cm
  • Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • American Society of Anesthesiology (ASA) classⅠ to Ⅲ lesions
  • After the evaluation of Multi-disciplinary team (MDT)
  • Written informed consent

Exclusion

  • T4 tumor that invade the external sphincter or levator ani muscle or neighbor organs
  • Recurrent rectal cancer
  • Distant metastasis
  • Obstructing rectal cancer
  • Synchronous colon cancer
  • Pregnant or breast-feeding women
  • Fecal incontinence
  • History of prior colorectal cancer
  • History of inflammatory bowel disease
  • Other malignancies diagnosed within the previous year
  • Mental illness
  • Any evidence of active infection
  • History of bleeding diathesis or coagulopathy
  • Impaired renal or hepatic function that could not tolerate surgery

Key Trial Info

Start Date :

September 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2016

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT02236884

Start Date

September 1 2014

End Date

June 1 2016

Last Update

December 19 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Gastrointestinal Hospital, Sun Yatsen University

Guangzhou, Guangdong, China, 510655

The Feasibility and Safety of No-scar Transanal Total Mesorectal Excision for Rectal Cancer | DecenTrialz